Should You Go For This US Penny Stock-QSI

Acrobull Canada Advisory Inc.

November 14

2024

Name	Ticker	Sector/Industry	Market Cap	Risk Factor
Quantum-Si incorporated	QSI-NASDAQ	Healthcare	$112.65 Million	High

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS).

Recent Highlights

Oversold Conditions- The company financial results have displayed some confidence and has shown that future lies good for the company.

Third quarter revenue is at $787,000 which is significantly good as compare to the previous quarter, we expect the company to generate short to mid-term results hence approach can be taken in to the stock.

Third Quarter 2024 Financial Highlights

The reported revenue for the third quarter of 2024 was $787,000.

Liberate Bio announced that it has integrated Platinum® Next-Generation Sequencing into their platform for generating innovative gene therapies with better targeting capabilities.

Todd Bennett, an industry veteran, has been appointed as Chief Commercial Officer ("CCO"), John Vieceli, Ph.D. as Chief Product Officer, and Lindsay Thompson as Chief Human Resources Officer.

Platinum-based advancements in proteome analysis were highlighted during the Human Proteome Organization World Congress 2024 in Dresden, Germany.

Highlighted a study from researchers at the University of Virginia published on BioRxiv showcasing Platinum's potential to differentiate peptide variations at single amino acid resolution.

Stock Observation- The company stock earnings have been average, however since the stock belonged to healthcare medical sector which has been oversold since last 2 years may generate short to mid-term results. The RSI level for the stock is at 42 which shows oversold conditions.

Risk Involved- Financial performance of the company may have an impact on the company stock performance.

Considering all the factors and financials of the company Acrobull Canada Advisory Inc. maintains Customer Choose Buy for the stock.

Disclaimer- Though our research is fundamentally and technically based on Acrovest only provides general advice on the stocks and it is imperative for the investors to do the risk assessment for themselves before investing as Acrovest would not be liable for any loss or profit arising out through the investment made by the investors on our recommendations.

It is also advisable for the investors to consult with Financial Advisor, Broker or to seek any legal assistance as the research conducted by Acrobull Canada Advisory Inc. is factually based and recommendations are given in accordance with that, but it is imperative to understand that Acrobull Canada Advisory Inc. does not guarantee returns.

Acrobull Recommendation Based on Evaluation

Current Market Price	$0.79 USD
Acrobull Recommendation	Buy
Target Price	$0.88 USD
RSI Level	14 Day RSI 42
Total Shares Outstanding	122.42 Million
Shares held by Insiders Risk Factor Stop Loss	19.91% Medium 5%